Literature DB >> 17509982

T-cell large granular leukemia and related proliferations.

Dennis P O'Malley1.   

Abstract

Session 9 of the 2005 Society for Hematopathology/European Association for Haematopathology Workshop focused on large granular lymphocyte (LGL) leukemias and related disorders. T-cell LGL (T-LGL) leukemias, discussed herein, account for 2% to 3% of cases of small lymphocytic leukemia. T-LGL diseases cover a heterogeneous spectrum of disorders that include reactive conditions, typically associated with autoimmune disease, to outright leukemia. These disorders are found in older people, with an average age at initial examination of approximately 60 years and a median survival of more than 10 years in T-LGL leukemia. Systemic symptoms and neutropenia are common at initial examination. Lymphocytosis, composed of small mature lymphocytes with increased cytoplasm, is common. The spleen and bone marrow are involved in T-LGL leukemia, although morphologic findings may be subtle. The immunophenotype is typically that of CD3+/CD8+ cytotoxic T cells. Some cases may be due to chronic immune stimulation, with subsequent clonal escape and proliferation of a neoplastic population of lymphocytes.

Entities:  

Mesh:

Year:  2007        PMID: 17509982     DOI: 10.1309/A8FHDA0VVRJ05GJP

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

1.  Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia.

Authors:  Adam W Mailloux; Ling Zhang; Lynn Moscinski; John M Bennett; Lili Yang; Sean J Yoder; Gregory Bloom; Cody Wei; Sheng Wei; Lubomir Sokol; Thomas P Loughran; Pearlie K Epling-Burnette
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

2.  Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia.

Authors:  Vivek Subbiah; Aaron D Viny; Steven Rosenblatt; Brad Pohlman; Alan Lichtin; Jaroslaw P Maciejewski
Journal:  Exp Hematol       Date:  2008-06-11       Impact factor: 3.084

3.  High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology.

Authors:  Ozlen Bektas; Aysegul Uner; Seda Muruvvet Aydin; Eylem Eliacik; Burak Uz; Ayse Işık; Ibrahim Celalettin Haznedaroğlu; Hakan Goker; Nilgun Sayinalp; Salih Aksu; Halûk Demiroglu; Osman Ilhami Ozcebe; Yahya Buyukasik
Journal:  Int J Hematol       Date:  2015-05-26       Impact factor: 2.490

4.  CD56 Negative Aggressive T Cell Large Granular Lymphocytic Leukemia.

Authors:  Mary Theresa Sylvia; Sajini Elizabeth Jacob; Debdatta Basu; Deepak Amalnath; Tarun Kumar Dutta
Journal:  Indian J Hematol Blood Transfus       Date:  2015-01-13       Impact factor: 0.900

Review 5.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

6.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 7.  Peripheral T and NK cell non-hodgkin lymphoma a challenge for diagnosis.

Authors:  Daniela Vasile; Ana-Maria Vladareanu; Horia Bumbea
Journal:  Maedica (Buchar)       Date:  2014-03

Review 8.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

9.  The gammadelta variant of T cell large granular lymphocyte leukemia is very similar to the common alphabeta type: report of two cases.

Authors:  Gene R Shaw; Vinay S Naik
Journal:  J Hematop       Date:  2008-08-23       Impact factor: 0.196

10.  Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes.

Authors:  Mithun Vinod Shah; Ranran Zhang; Rosalyn Irby; Ravi Kothapalli; Xin Liu; Ty Arrington; Bryan Frank; Norman H Lee; Thomas P Loughran
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.